Although the company's advancements have influenced contemporary healthcare, its stock presents a more cautious narrative ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and ...

The FDA approved the protocol update, significantly expanding patient eligibility criteria for enrollment in the study.

Orchestra BioMed announced today that it completed strategic transactions and equity offerings worth an expected $111.2 ...

FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the ...

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, ...

Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to inve ...

Carol Seeger finally escaped her debilitating depression with an experimental treatment that placed electrodes in her brain and a pacemaker-like device in her chest. But when its batteries stopped ...

A new adaptive brain implant for Parkinson’s acts like a pacemaker, adjusting stimulation in real-time to improve symptoms and quality of life significantly.

In 2023, a jury found that Medtronic infringed on a patent for a heart valve replacement method developed by Colibri Heart Valve.